BN201 SAD MAD Study in Healthy Subjects

Optic Neuritis Clinical Trial

Official title:

A Randomised, Double-blind, Placebo-controlled, Single (SAD) and Multiple Ascending Dose (MAD) Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BN201 in Healthy Subjects

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03630497
• Other study ID #: BN201_RDREG_251
• Secondary ID: 2017-001202-14
• Status: Completed
• Phase: Phase 1
• Start date: May 27, 2018
• Est. completion date: February 22, 2019

Study information

• Verified date: April 2019
• Source: Bionure Farma SL
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple doses of BN201 in healthy subjects.

This is a phase I, randomised, double-blind, placebo-controlled study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of BN201 in healthy subjects following single ascending doses and two cohorts of multiple doses. The study will be conducted in two parts (Part A and Part B). Part A (up to 8 single ascending doses (SD)) will be conducted in 32 subjects (4 interlocking cohorts of 8 subjects). Part B (up to 2 multiple ascending doses (MD)) will be conducted in 16 subjects (2 cohorts of 8 subjects). Subjects in Part A will undergo a screening period (Day -28 to Day -2), two in-patient treatment periods compromising 3 overnight stays (from Day -1 to Day 3) with a wash out period of at least 14 days between dose administrations and a follow up visit 12 to 16 days following administration of IMP. Subjects in Part B will undergo a screening period (Day -28 to Day -2), an in-patient treatment period compromising 7 overnight stays (from Day -1 to Day 7) and a follow up visit 12 to 16 days following final administration of Investigational Medicinal Product (IMP).

Description:

Screening (Days -28 to -2) Screening assessments will be performed within 28 days of the first dose to ensure the eligibility of participants. Assessments will include medical history, demographics, concomitant medication check, physical examination, body weight, height, BMI, HIV, Hepatitis B and Hepatitis C screen, drugs of abuse and alcohol screen, routine laboratory assessments (biochemistry, haematology and urinalysis), 12-lead ECG, EEG monitoring, brain MRI scan, vital signs (supine systolic and diastolic blood pressure, pulse) and body temperature. Female participants will also be screened for pregnancy and hormone status. A C-SSRS questionnaire will also be performed at screening for Part B only.

Treatment Period

Part A:

Up to four cohorts ((SD1), (SD2), (SD3), (SD4)) of eight subjects will be randomly assigned to receive either two single intravenous doses of BN201, two single intravenous doses of placebo or one single intravenous dose of BN201 and placebo (per treatment period) over two treatment periods (Period 1 and Period 2). Within each cohort, 6 subjects will receive BN201 and 2 subjects will receive placebo. Two "dose leader" subjects will be dosed on the same day, at least 48 h before the remaining subjects in the cohort. Of these two subjects, one will be dosed with BN201 and the other with placebo. The Chief Investigator (or delegate) must confirm it is safe to continue with the dosing of the remainder of the cohort following review of appropriate safety data. The remaining 6 subjects of the cohort (five randomised to active and one to placebo) will then be dosed.

Subjects will be admitted to the clinical unit in the morning of Day -1 and will remain in the unit until the 48 h post dose scheduled assessments and procedures have been performed (Day 3). On Day -1 of each Treatment Period subjects' eligibility will be re-assessed and blood and urine samples will be collected for laboratory safety tests (including drugs of abuse and alcohol screen, biochemistry, haematology, urinalysis and serum pregnancy test). A 12-lead ECG, vital signs (supine systolic and diastolic blood pressure, pulse), body temperature, adverse event and concomitant medication checks will be performed. The intravenous dose of BN201 or placebo will be based on body weight measured on Day -1. An evening snack will be consumed at least 10 hours (h) before (each) dose administration.

After an overnight fast of at least 10 h, dose administration will occur on the morning of Day 1 between 08:00 and 11:00 whilst subjects are in a semi supine position. The subjects will remain in this position until 2 h post-infusion, however other positions are temporarily allowed for scheduled assessment requirements. Fasting will continue until 4 h after start of infusion; a standardised meal will then be administered.

Subjects will be discharged from the clinical unit on Day 3 (48 h post-dose) providing there are no ongoing safety concerns. There will be a wash out period of at least 14 days between dose administrations prior to subjects returning for their treatment 2 scheduled assessments and procedures.

The following assessments will be made during treatment Period 1 and Period 2:

• Safety assessments: Adverse event (AEs) and concomitant medication check, physical examination, laboratory safety assessments (drugs of abuse and alcohol screen, biochemistry, haematology, urinalysis and serum pregnancy test), 12-lead ECG, telemetry, Holter monitoring, EEG monitoring, vital signs (supine systolic and diastolic blood pressure, pulse) and body temperature, infusion site reaction assessment.

• Pharmacokinetics (PK) assessments: Blood sample collection for measurement of BN201 in plasma.

• Pharmacodynamics (PD) assessments: Blood sample collection for measurement of phosphorylation of N-myc downstream-regulated gene 1 (NDGR1) in peripheral blood mononuclear cells (PBMCs).

• Pharmacogenomic assessments: Blood sample will be collected for potential genotyping of deoxyribonucleic acid (DNA) sequence variants to explore potential relationships with PK/PD and or tolerability.

A follow-up visit (including a brain MRI scan) will be conducted 12 to 16 days following each administration of IMP. If all follow-up assessments are satisfactory to the Investigator following Treatment Period 2 the subject will be discharged from the study. If any AEs are ongoing, or any assessments not satisfactory subjects may be recalled to the unit for follow-up assessments until the Investigator is satisfied the subject may be discharged from the study. Subjects will be advised to return or contact the unit at any time if they may be experiencing any adverse effects.

Enrolment of the subsequent cohort will only proceed, if blinded PK and safety data from the previous cohort has been reviewed by the Sponsor and Chief Investigator and is found to be satisfactory.

Part B:

Two cohorts (MD1, MD2) of eight subjects will be randomly assigned to receive either multiple intravenous doses of BN201 or multiple intravenous doses of placebo once daily for five consecutive days (Day 1 to Day 5). Within each cohort, 6 subjects will receive BN201 and 2 subjects will receive placebo. Two "dose leader" subjects will be dosed on the same day, at least 48 h before the remaining subjects in the cohort. Of these two subjects, one will be dosed with BN201 and the other with placebo. The Chief Investigator (or delegate) must confirm it is safe to continue with the dosing of the remainder of the cohort following review of appropriate safety data. The remaining 6 subjects of the cohort (five randomised to active and one to placebo) will then be dosed. The dose levels to be administered will be based on the safety, tolerability and PK results of Part A. Cohort MD1 can only be started if a higher dose level in the SAD part was well tolerated and that simulated PK modelling for multiple dose administration based on PK data from single doses do not suggest that the Cmax threshold of 13.3 μg/mL will be exceeded. Enrolment of MD2 will only proceed if blinded PK and safety data from subjects in MD1 has been reviewed by the Sponsor and Chief Investigator and is found to be satisfactory. A lower dose may be chosen if deemed appropriate following review of PK and safety data from Part A.

Subjects will be admitted to the clinical unit in the morning of Day -1 and will remain in the unit until the scheduled assessments and procedures have been performed on Day 7, 48 h post-last dose. On Day -1 subjects' eligibility will be re-assessed and blood and urine samples will be collected for laboratory safety tests (including drugs of abuse and alcohol screen, biochemistry, haematology, urinalysis and serum pregnancy test). A 12-lead ECG, vital signs (supine systolic and diastolic blood pressure, pulse), body temperature, quantitative sensory testing (QST) and visual analogue scale (VAS) and adverse event and concomitant medication checks will be performed. The intravenous dose of BN201 or placebo will be based on body weight measured on Day -1. An evening snack will be consumed at least 10 h before (each) dose administration.

After an overnight fast of at least 10 h, dose administration will occur on the mornings of Day 1 to Day 5 between 08:00 and 11:00 whilst subjects are in a semi supine position. The subjects will remain in this position until 2 h post-infusion, however other positions are temporarily allowed for scheduled assessment requirements. Fasting will continue until 4 h after start of infusion; a standardised meal will then be administered.

Subjects will be discharged from the clinical unit on Day 7 providing there are no ongoing safety concerns. The following assessments will be made during Day -1 to Day 7:

• Safety assessments: Adverse event (AEs) and concomitant medication check, physical examination, laboratory safety assessments (drugs of abuse and alcohol screen, biochemistry, haematology and urinalysis and serum pregnancy test), 12-lead ECG, telemetry, Holter monitoring, EEG monitoring*, vital signs (supine systolic and diastolic blood pressure, pulse) and body temperature, infusion site reaction assessment, C-SSRS questionnaire, QST and VAS.

• PK assessments: Blood sample collection for measurement of BN201 in plasma.

• PD assessments: Blood sample collection for measurement of phosphorylation of N-myc downstream-regulated gene 1 (NDGR1) in peripheral blood mononuclear cells (PBMCs).

• Pharmacogenomic assessments: Blood sample will be collected for potential genotyping of deoxyribonucleic acid (DNA) sequence variants to explore potential relationships with PK/PD and or tolerability.

• EEG monitoring only performed for Part B Cohort 2 if indicated from results from Part B Cohort 1

A follow-up visit (including a brain MRI scan) will be conducted 12 to 16 days following the subjects' final administration of IMP. If all follow up assessments are satisfactory to the Investigator, the subject will be discharged from the study. If any AEs are ongoing, or any assessments not satisfactory subjects may be recalled to the unit for follow-up assessments until the Investigator is satisfied the subject may be discharged from the study. Subjects will be advised to return or contact the unit at any time if they may be experiencing any adverse effects.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 48
• Est. completion date: February 22, 2019
• Est. primary completion date: February 1, 2019
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 55 Years

Eligibility

Inclusion Criteria:

To be confirmed at screening:

1. Healthy male and female subjects between 18 and 55 years of age.

2. *Healthy subjects as determined by past medical history and as judged by the PI (including no significant infection in the last 3 months before trial enrolment).

3. *Female subject of non-child bearing potential with negative pregnancy test at screening and each admission to the clinical unit. For the purposes of this study, this is defined as the subject being amenorrheic for at least 12 consecutive months or at least 4 months post-surgical sterilisation (including bilateral fallopian tube ligation or bilateral oophorectomy with or without hysterectomy). Menopausal status will be confirmed by demonstrating at screening that levels of follicle stimulating hormone (FSH) fall within the respective pathology reference range. In the event a subject's menopause status has been clearly established (for example, the subject indicates she has been amenorrheic for 10 years), but FSH levels are not consistent with a post-menopausal condition, determination of subject eligibility will be at Investigator's discretion following consultation with the Sponsor.

4. *Female subjects of child bearing potential must be non-pregnant and non-lactating with negative pregnancy test at screening and each admission to the clinical unit.

5. *Female subjects of child bearing potential and male subjects with female partners of child bearing potential must take one highly effective contraceptive precaution in addition to one acceptable contraceptive precaution (i.e., barrier precaution) from first dose until 3 months after last dose of IMP (as detailed in Section 9.4.1).

6. *Male subject willing to use an effective method of contraception or 2 effective methods of contraception, i.e., highly effective method of contraception + condom, if applicable (unless anatomically sterile or where abstaining from sexual intercourse is in line with the preferred and usual lifestyle of the subject) from first dose until 3 months after last dose of IMP.

7. *Subject with a body weight of = 50.0 kg and =100 kg and have a body mass index (BMI) of 18-32 kg/m2. BMI = body weight (kg) / [height (m)]2.

8. *Subject with no clinically significant history of previous allergy / sensitivity to BN201 or any of the excipients contained within the IMP.

9. *Subject with no clinically significant abnormal serum biochemistry, haematology and urine examination values within 28 days before the first dose of IMP.

10. *Subject with a negative urinary drugs of abuse screen, determined within 28 days before the first dose of IMP (N.B. a positive alcohol result may be repeated at Investigator's discretion).

11. Subject with negative human immunodeficiency virus (HIV) and hepatitis B surface antigen (HBsAg) and hepatitis C virus antibody (HCV) results.

12. *Subject with no clinically significant abnormalities in 12-lead electrocardiogram ((QTcF = 430 ms) and (PR 120 - 200 ms)) determined within 28 days before first dose of IMP.

13. Subjects with no clinically significant abnormalities in electroencephalogram (EEG) determined within 28 days before first dose of IMP.

14. *Subject with no clinically significant abnormalities in vital signs (supine systolic and diastolic blood pressure, pulse) and body temperature determined within 28 days before first dose of IMP.

15. Subject must be available to complete the study (including all follow up visits).

16. Subject must satisfy the investigator / designee about their fitness to participate in the study.

17. Subject must be willing and able to sign the written informed consent to participate in the study.

18. Subjects must not donate sperm for the first dose and for at least 3 months after the last dose of IMP.

19. Subject with no clinically significant abnormalities in brain MRI scan determined within 28 days before first dose of IMP.

To be re-confirmed on Day -1 / prior to dosing:

1. Subject continues to meet all screening inclusion criteria indicated with * (BMI will only apply to screening).

2. Subject with a negative urinary drugs of abuse screen (including alcohol) prior to dosing.

3. Female subject with negative pregnancy test.

Exclusion Criteria:

To be confirmed at screening:

1. Use of prescription or non-prescription drugs, including vitamins, herbal and dietary supplements within 14 days or 5 half-lives (whichever is longer) prior to the first dose of IMP, unless in the opinion of the Investigator the medication will not interfere with the study procedures or compromise subject safety.

2. Evidence of renal, hepatic, central nervous system, respiratory, cardiovascular or metabolic dysfunction.

3. A clinically significant history of drug or alcohol abuse.

4. Users of nicotine products i.e., current smokers or ex-smokers who have smoked within the 6 months prior to dosing with the study medication or users of cigarette replacements (i.e., e-cigarettes, nicotine patches or gums).

5. Inability to communicate well with Investigators (i.e., language problem, poor mental development or impaired cerebral function).

6. Participation in a New Chemical Entity clinical study within the previous 3 months or a marketed drug clinical study within the 30 days before the first dose of IMP. (Washout period between studies is defined as the period of time elapsed between the last dose of the previous study and the first dose of the next study).

7. Donation of 450 mL or more blood within the 3 months before the first dose of IMP.

To be re-confirmed at Day -1 / prior to dosing:

1. Development of any exclusion criteria since screening.

2. Use of prescription or non-prescription drugs, including vitamins, herbal and dietary supplements since screening, unless in the opinion of the Investigator and Sponsor's Responsible Physician the medication will not interfere with the study procedures or compromise subject safety.

3. Participation in a clinical study since the screening visit.

4. Donation of 450 mL or more blood within the 3 months before the first dose of IMP and until at least 3 months after the final study visit.

Related Conditions & MeSH terms

• Demyelinating Diseases
• Neuritis
• Optic Neuritis
• Optic; Neuritis, With Demyelination

Intervention

Drug:
• Comparison of BN201 treatment with Placebo
Single Dose or Multiple Dose of BN201 IV administration

Locations

Country	Name	City	State
United Kingdom	Simbec Research Limited	Merthyr Tydfil

Sponsors (2)

Lead Sponsor	Collaborator
Bionure Farma SL	Simbec Research

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Pharmacodynamic Parameter: Phosphorylation of N-myc downstream regulated 1 (NDRG1) measurement	NDRG1 phosphorylation in PBMCs	Up to 2 hours post start infusion
Other	Pharmacogenomics Parameter: Sequencing of DNA in blood samples	Potential genotyping of deoxyribonucleic acid (DNA) sequence variants in blood sample	Day 1
Primary	Safety: Adverse Events (AEs) and serious adverse events (SAEs) Reporting	All AEs will be recorded, whether considered minor or serious, drug-related or not.	Up to 17 days
Primary	Safety: Routine Laboratory Safety Screen on Haematology	Analysis for Haematology	Up to 17 days
Primary	Safety: Routine Laboratory Safety Screen on Urinary Sodium	Analysis for Urinary Sodium	Up to 17 days
Primary	Safety: Routine Laboratory Safety Screen on Biochemistry	Analysis for Biochemistry	Up to 17 days
Primary	Safety: Routine Laboratory Safety Screen on Urinary Potassium	Analysis for Urinary Potassium	Up to 17 days
Primary	Safety: Vital signs Measures on Systolic blood pressure	Check of Systolic blood pressure	Up to 17 days
Primary	Safety: Vital signs Measures on Diastolic blood pressure	Check of Diastolic blood pressure	Up to 17 days
Primary	Safety: Vital signs Measures on oral body temperature	Check of oral body temperature	Up to 17 days
Primary	Safety: Vital signs Measures on Pulse rate	Check of pulse rate	Up to 17 days
Primary	Magnetic resonance imaging (MRI) brain scan	Non-contrast MRI brain scans	Up to 17 days
Primary	Safety: Suicide Risk assessement	Assessment of Suicide-related thoughts and behaviours using Columbia-Suicide Severity Rating Scale (C-SSRS) Questionnaire	Up to 17 days
Primary	Safety: Physical Examination for ear	Examination of ear	Up to 17 days
Primary	Safety: 12-lead Electrocardiography (ECG) Recording	Performance of ECGs in the supine position	Up to 17 days
Primary	Safety: Telemetry Monitoring	Cardiac rhythm measure	Up to 5 days
Primary	Safety: Pain report	Spontaneous (neuropathic) pain report using Visual Analogue Scale (VAS) tool	Day 5
Primary	Safety: Quantitative Sensory Testing (QST)	Evaluation of increase in mechano-sensitivity	Day 5
Primary	Safety: Infusion Site Reaction Assessment	Assessment of Infusion Site Reaction	Up to 17 days
Primary	Safety: Holter Monitoring	Cardiac rhythm measure	Up to 5 days
Primary	Safety: Electroencephalography (EEG) Recording	Electrical activity measure	Up to 5 days
Primary	Safety: Concomitant Medication Recording	All prior and concomitant medications taken record	Up to 17 days
Primary	Safety: Physical Examination for nose	Examination of nose	Up to 17 days
Primary	Safety: Physical Examination for throat	Examination of throat	Up to 17 days
Primary	Safety: Physical Examination for eye	Examination of ophthalmological aspects	Up to 17 days
Primary	Safety: Physical Examination for skin	Examination of dermatological aspects	Up to 17 days
Primary	Safety: Physical Examination for cardiovascular	Examination of cardiovascular aspects	Up to 17 days
Primary	Safety: Physical Examination for Respiratory	Examination of respiratory aspects	Up to 17 days
Primary	Safety: Physical Examination for gastrointestinal	Examination of gastrointestinal aspects	Up to 17 days
Primary	Safety: Physical Examination for Central Nervous System	Examination of central nervous system	Up to 17 days
Primary	Safety: Physical Examination for Lymph Nodes	Examination of lymph nodes	Up to 17 days
Primary	Safety: Physical Examination for musculoskeletal	Examination of musculoskeletal aspects	Up to 17 days
Secondary	Pharmacokinetic Parameter: Cmax measurement	Maximum concentration measurement in plasma	From pre-dose to 24 hours post-start-infusion
Secondary	Pharmacokinetic Parameter: Tm concentration measurement	Time to maximum observed concentration in plasma	From pre-dose to 24 hours post-start-infusion
Secondary	Pharmacokinetic Parameter: kel measurement	Elimination rate constant in plasma	From pre-dose to 24 hours post-start-infusion
Secondary	Pharmacokinetic Parameter: t1/2 measurement	Terminal elimination half-life in plasma	From pre-dose to 24 hours post-start-infusion
Secondary	Pharmacokinetic Parameter: AUC 0-t measurement	Area under the concentration-time curve (AUC) from 0 to t, where t is the dosing interval (0 - 24 h) in plasma	From pre-dose to 24 hours post-start-infusion
Secondary	Pharmacokinetic Parameter: AUC 0-t measurement	Area under the concentration-time curve (AUC) from the time of dosing to the time of the last measurable concentration in plasma	From pre-dose to 24 hours post-start-infusion
Secondary	Pharmacokinetic Parameter: AUC 0-inf measurement	AUC extrapolated to infinity	From pre-dose to 24 hours post-start-infusion
Secondary	Pharmacokinetic Parameter: AUC % measurement	extrapolated Residual area	From pre-dose to 24 hours post-start-infusion
Secondary	Pharmacokinetic Parameter: Clearance (CL) measurement	Clearance	From pre-dose to 24 hours post-start-infusion
Secondary	Pharmacokinetic Parameter: Vz measurement	Volume of distribution	From pre-dose to 24 hours post-start-infusion